Most people searching for essential tremor are not really asking what it is. They are asking whether the shaking is Parkinson's disease. That has a reasonably clear answer. We sell supplements; nothing we sell treats essential tremor, Parkinson's or any other movement disorder, and there is no product recommendation below.
The International Parkinson and Movement Disorder Society's consensus statement on the classification of tremors defines essential tremor as an isolated tremor syndrome of bilateral upper limb action tremor, of at least three years' duration, with or without tremor in other locations such as head, voice or lower limbs, and with an absence of other neurological signs such as dystonia, ataxia or parkinsonism. Action tremor means tremor appearing when a position is held against gravity or during movement.
Parkinsonian tremor is the near-opposite on most of those axes. The same consensus statement describes tremor combined with parkinsonism — that is, with bradykinesia and rigidity — as typically a 4 to 7 Hz rest tremor of the hand, lower limb, jaw, tongue or foot, unilateral in onset. The most useful difference is what the tremor does when the hand starts working:
Two caveats stop that being a self-diagnosis tool. Parkinson's rest tremor can re-emerge after a delay once a new posture is held, and the consensus statement classifies that re-emergent tremor as an action tremor. And frequency is close to useless here: the statement says it "is not very helpful in diagnosis because the frequency of most pathological tremors is 4 to 8 Hz".
One further classification point. Essential tremor with tremor at rest is not classified as essential tremor at all. It becomes essential tremor plus, the label for tremor with the features of essential tremor plus additional signs of uncertain significance — impaired tandem gait, questionable dystonic posturing, memory impairment. Rest tremor does not mean Parkinson's, and it does not mean plain essential tremor either.
How often is this missed? At one specialist centre, 71 consecutive patients arrived with an existing diagnosis of essential tremor and were re-evaluated against consensus criteria. Twenty-six (37%) were misdiagnosed: Parkinson's disease in 11, dystonia in 6, Parkinson's with essential tremor in 5, other disorders in 4. That is a referral-clinic figure, not a population rate, and its odds ratios for predictive features are very imprecise — unilateral arm tremor gave an odds ratio of 10.5, 95% CI 1.2 to 95.4 (P = .02). The direction is informative; the magnitude is not.
The most recent systematic review of population-based prevalence studies pooled 42 studies across 23 countries and six continents: 3,263 cases among 540,558 people screened.
An I² of 99.3% means almost none of the spread between those studies is sampling noise. The review names the causes: differences in ascertainment, case evaluation, case definition and study demographics. Studies that stated an explicit definition of essential tremor pooled to 2.00% (95% CI 1.31% to 3.03%); studies that did not pooled to 0.10% (95% CI 0.04% to 0.26%). A twenty-fold gap, created by whether researchers wrote down what they were counting. Any single figure is therefore a choice of method; the defensible summary is roughly one in a hundred overall, rising steeply to near one in twenty over 65.
The American Academy of Neurology's guideline was published in 2011, updating a 2005 practice parameter now marked retired. The AAN's own guideline page records that the 2011 update was reaffirmed by its Guidelines Subcommittee on 19 July 2025, so it stands.
Its top recommendation, verbatim from the AAN clinician summary: "Propranolol, propranolol long-acting, or primidone should be offered to patients who desire treatment for limb tremor in ET, depending on concurrent medical conditions and potential side effects (Level A)". Level A means established as effective.
Note what carries that grade: the drugs. Not a dose. The guideline's dose-related statement sits much lower — that dosages may need increasing by 12 months of therapy, Level C. Two further recommendations sit below Level A: that either drug may be used as initial therapy (Level B), and that the two may be combined when monotherapy is insufficient (Level B). Propranolol for head rather than limb tremor is Level B. Both are prescription medicines; nothing here is dosing guidance or a reason to start, stop or change a prescription.
The underlying trials are small and old. In a double-blind placebo-controlled study of primidone in hand and head tremor, primidone beat placebo for hand tremor magnitude, comparably to propranolol — and no consistent attenuation of head tremor was found. An acute toxic reaction to the first small dose occurred in six of 22 patients. A double-blind randomised crossover study compared primidone, propranolol and placebo in 14 patients using accelerometry: both drugs beat placebo (p < 0.01 each), with no significant difference between the two drugs.
The summary's clinical context section carries the number we most want readers to have. In a survey of 223 patients in a clinical database, 70.9% had taken primidone or propranolol and 56.3% had discontinued one or both. The AAN's conclusion: "these first-line medications for ET clearly fail to meet the needs of many patients".
The 2011 guideline predates MR-guided focused ultrasound, so its grades do not cover it. What it does say: deep brain stimulation of the ventral intermediate thalamic nucleus may be used for medically refractory limb tremor (Level C); unilateral thalamotomy may be used (Level C) but bilateral thalamotomy is not recommended because of side effects (Level C); DBS has fewer adverse events than thalamotomy (Level B); and evidence on gamma knife thalamotomy is insufficient (Level U). Gamma knife radiosurgery is not focused ultrasound, so that Level U does not transfer. Of surgery generally the guideline adds: "No high-quality, long-term studies exist regarding the efficacy and safety of these interventions for ET".
Sham-controlled evidence for focused ultrasound arrived in 2016. Seventy-six patients with moderate-to-severe tremor unresponsive to at least two drug trials were randomised 3:1 to unilateral focused ultrasound thalamotomy or sham, with assessments videotaped and rated by neurologists blind to assignment. Hand-tremor scores fell from 18.1 to 9.6 after thalamotomy and from 16.0 to 15.8 after sham; the between-group difference was 8.3 points on a 32-point scale (95% CI 5.9 to 10.7, P < 0.001). Gait disturbance occurred in 36% and paraesthesias or numbness in 38%, persisting at 12 months in 9% and 14%.
Everything after three months is uncontrolled, because the sham group could cross over. The trial's 12-month figure — a 7.2-point change from baseline (95% CI 6.1 to 8.3) — is a within-group change, not a placebo-controlled one. So is the five-year follow-up, in which the 40 patients still assessed had combined tremor and motor scores 40.4% improved from baseline.
Nobody has randomised focused ultrasound against DBS. A meta-analysis of five cohort studies and 463 patients found a significant difference in total tremor score favouring DBS (mean difference 5.12, 95% CI 1.08 to 9.16, P = 0.01) — but no significant difference on CRST part A (P = 0.15) and none in response rate (P = 0.56). Paraesthesia (13.3% vs 2.2%), gait instability (26.6% vs 4.1%) and dysphagia (7.8% vs 1.4%) were more frequent with focused ultrasound, the last only marginally (risk ratio 3.40, 95% CI 1.01 to 11.46), while infection and haemorrhage were more common with DBS but did not differ significantly. The authors note the tremor-score advantage may reflect bilateral DBS being compared with predominantly unilateral focused ultrasound. Nor is DBS permanent in effect: a network meta-analysis of 52 studies found efficacy declining about 1.2 points a year, losing almost half the initial benefit within ten years, with no significant advantage for bilateral over unilateral implantation.
Set aside for a moment what alcohol does to the brain more generally. The tremor phenomenon is real and was pinned down in 1975. Five patients had marked reduction in tremor amplitude within 15 minutes of a small oral dose of ethanol. When the same patients received equivalent ethanol infused into a brachial artery, there was no reduction in the perfused limb — evidence the effect is central, not peripheral.
It is common but neither universal nor predictable. Using a validated spiral-drawing test in 104 patients, each also performing an identical test without alcohol to quantify measurement variability, alcohol sensitivity was demonstrable in 46%. Sex, family history, diagnostic certainty and — notably — the patient's own reported history of alcohol responsiveness did not predict the measured response. A study of 24 patients from families with confirmed essential tremor found an objective response in 67%. The consensus statement declined to put alcohol response in the definition of essential tremor on these grounds: such features "are not consistent enough to be included".
The effect is also brief. In the study that developed the test — 10 patients measured in a laboratory and 15 testing at home — improvement reached up to 50% across outcome measures, but tremor deteriorated after three hours, the authors concluding it "is only short-lived and exhibits a rebound after > 3 hours and the next morning". The 104-patient cohort reported the same next-morning rebound with increased tremor intensity. The familial study dissents on that specific point: median spiral scores were 5.0 before alcohol, 3.25 an hour after and 4.75 the next morning, and its authors found no statistically significant difference between baseline and the next morning — "no rebound effect (p = 0.166)". So a rebound above baseline is reported but not unanimous. What all three agree on is that the benefit is not there the next morning.
This is not a management strategy and we are not presenting it as one. Reviews of alcohol use in movement disorders are consistent on this: the brief duration of action, the rebound that follows it, and the risk of developing alcohol dependence together make alcohol inappropriate as a treatment for essential tremor. Something that works for under three hours, needs repeat dosing all day and carries dependence liability is not a treatment.
One related claim runs the other way. Whether essential tremor raises alcoholism risk has been studied, and the controlled answers were null: controlled comparisons have found drinking frequency and quantity largely similar to general-population samples, and pathological drinking no more prevalent than in other tremor disorders or in chronic neurological disease generally. Those nulls are not permission. Drinking regularly to suppress a symptom carries the ordinary risks of drinking regularly, and the dose has to keep coming.
Nothing in our range treats essential tremor. We sell magnesium glycinate, omega-3 and three sleep and cognitive products. We searched for randomised trials of those ingredients in essential tremor populations and found none, which is why there is no evidence section about them here — the same standard we apply to everything we decline to stock. Essential tremor is diagnosed and managed by a neurologist, with prescription medicines and, in refractory cases, procedures.
This article is general information, not medical advice. It is not intended to diagnose, treat, cure or prevent any disease, and nothing in it is a reason to start, stop or change any prescribed medicine. Tremor warrants assessment by a doctor. Written 18 October 2026.